6/27/23, 11:48 PM Benazepril in Severe CKD Pathway Feedback Search Clinical Topics Home Studies Benazepril in Severe CKD Benazepril in Severe CKD Disease Chronic kidney disease Trial question What is the role of benazepril in patients without diabetes who had advanced renal insufficiency? Study design Single center Double blinded RCT Population Characteristics of study participants 50.0% female N = 224 50.0% male 224 patients (113 female, 111 male) Inclusion criteria: patients without diabetes who had advanced renal insufficiency Key exclusion criteria: immediate need for dialysis; treatment with corticosteroids, non- steroidal anti-inflammatory drugs or immunosuppressive drugs; renovascular disease; myocardial infarction; connective-tissue disease; obstructive uropathy Interventions N=112 benazepril (20 mg per day) N=112 placebo (matching placebo per day) Primary outcome Death, end-stage renal disease, or doubling of serum creatinine 60 60.0 % 45.0 % 41 https://web.pathway.md/studies/recZ5wcYkSOULP3z7 1/2 6/27/23, 11:48 PM Benazepril in Severe CKD Pathway 41 30.0 % Significant decrease 15.0 % NNT = 5 0.0 % Benazepril Placebo Significant decrease in death, end-stage renal disease, or doubling of the serum creatinine (41% vs. 60%; RR 0.68, 95% CI 0.22 to 1.14) Secondary outcomes Significant increase in the percentage of patients achieving a reduction in proteinuria (52% vs. 20%; RR 2.6, 95% CI 1.06 to 4.14) Safety outcomes No significant difference in major adverse events. Conclusion In patients without diabetes who had advanced renal insufficiency, benazepril was superior to placebo with respect to death, end-stage renal disease, or doubling of the serum creatinine. Reference Hou FF, Zhang X, Zhang GH et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006 Jan 12;354(2):131-40. Open reference URL https://web.pathway.md/studies/recZ5wcYkSOULP3z7 2/2